A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)

Gynecologic Oncology

Volumn 118, Issue 3, 2010, Pages 308-312

  Hirte, H ^a   Oza, A ^b   Swenerton, K ^c   Ellard, S L ^c   Grimshaw, R ^d   Fisher, B ^e   Tsao, M ^b   Seymour, L ^e  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e Queen's Cancer Research Institute   (Canada)

Author keywords

Carboplatin; EGFR inhibition; Erlotinib; Ovarian cancer; Recurrent

Indexed keywords

CARBOPLATIN; ERLOTINIB;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; AMNESIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SENSITIVITY; DRY EYE; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INTESTINE OBSTRUCTION; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CA-125 ANTIGEN; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77955552371     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.05.005     Document Type: Article

References (47)

1. M. Monga, J.A. Carmichael, W.E. Shelley, W.E. Kirk, G.V. Krepart, and J.F. Jeffrey Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging Gynecol Oncol 43 1991 195 197
2. J.B. Vermorken, and S. Pecorelli Clinical trials in patients with epithelial ovarian cancer: past, present and future Eur J Surg Oncol 22 1996 455 466
3. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partrige, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
4. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonson Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results J Natl Cancer Inst 92 2000 699 798
5. A. du Bois, H.J. Luck, and T. Bauknecht First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group J Clin Oncol 17 1999 46 51
6. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
7. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 1999 241 250
8. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
9. S.B. Fox, K. Smith, J. Hollyer, M. Greenall, D. Hastrich, and A.L. Harris The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients Breast Cancer Res Treat 29 1994 41 49
10. D.W. Fry Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors Pharmacol Ther 82 1999 207 218
11. D.E. Neal, and K. Mellon Epidermal growth factor receptor and bladder cancer: a review Urol Int 48 1992 365 371
12. Ö. Alper, E.S. Bergmann-Leitner, T.A. Bennett, N.F. Hacker, K. Stromberg, and W.G. Stetler-Stevenson Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds J Natl Cancer Inst 93 2001 1375 1384
13. J.V. Ilekis, J.P. Connor, G.S. Prins, K. Ferrer, C. Niederberger, and B. Scoccia Expression of epidermal growth factor and androgen receptors in ovarian cancer Gynecol Oncol 66 1997 250 254
14. O.J. Owens, C. Stewart, I. Brown, and R.E. Leake Epidermal growth factor receptors (EGFR) in human ovarian cancer Br J Cancer 64 1991 907 910
15. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, and M.G. Kris Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 2000 4885 4892
16. J.M. Sewell, K.G. Macleod, A. Ritchie, J.F. Smyth, and S.P. Langdon Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa') Br J Cancer 86 2002 456 462
17. C. Cullinane, M. Kleinschmidt, and L.K. Webster Antitumour activity of ZD1839 in combination with cisplatin in NIH 3T3 cells expressing human epidermal growth factor receptor Proc Am Assoc Cancer Res 41 2000 482 abstract
18. V. Benedetti, P. Perego, G.L. Beretta, E. Corna, S. Tinelli, and S.C. Righetti Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol Cancer Ther 7 3 2008 679 687
19. C. Cao, S. Lu, A. Sowa, R. Kivlin, A. Amara, and W. Chu Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs Cancer Lett 266 2008 249 262
20. H.M. Coley, C.F. F. Shotton, A. Ajose-Adeogun, H. Modjtahedi, and H. Thomas Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents Biochem Pharmacol 72 2006 941 948
21. L.A. Knight, F. Di Nicolantonio, P. Whitehouse, S. Mercer, S. Sharma, and S. Glaysher The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours BMC Cancer 4 2004 83 90
22. T. Servidei, A. Riccardi, S. Mozzetti, C. Ferlini, and R. Riccardi Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib Int J Cancer 123 2008 2939 2949
23. A. Gordon, N. Finkler, R.P. Edwards, A.A. Garcia, M. Crozier, and D.H. Irwin Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 2005 785 792
24. R.J. Schilder, M.W. Sill, X. Chen, K.M. Darcy, S.C. Decesore, and C. Lewandowski Phase II trial of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal cancer and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecology Oncology Group Study Clin Cancer Res 11 2005 5539 5548
25. I.B. Vergote, Y. Humblet, E. van Cutsem, S. van Belle, J. Kerger, and J.-L. Van Laethem A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: interim data J Clin Oncol ASCO Annual Meeting Proceedings 23, No 16S 2005 3162 abstract
26. S. Campos, O. Hamid, M.V. Seiden, A. Oza, M. Plante, and R.K. Potkul Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer J Clin Oncol 23 2005 5597 5604
27. M.V. Seiden, H.A. Burris, U. Matulonis, S.B. Hall, D.K. Armstrong, and J. Speyer A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies Gynecol Oncol 104 2007 727 731
28. M.S. Gordon, D. Matei, C. Aghajanian, U.A. Matunlonis, M. Brewer, and G.F. Fleming Clinical activity of pertuzumab (rhuMab2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status J Clin Oncol 24 2006 4324 4332
29. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group J Clin Oncol 21 2003 283 290
30. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
31. M. Brundage, J. Pater, and B. Zee Assessing the reliability of two toxicity scales: implications for interpreting toxicity data J Natl Cancer Inst 85 1993 1138 1148
32. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumours (RECIST guidelines) J Natl Cancer Inst 92 2000 205 216
33. M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, and S. Rubin Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
34. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
35. S. Stadlmann, U. Gueth, U. Reiser, P.A. Diener, A.G. Zeimet, and E. Wight Epithelial growth factor receptor status in primary and recurrent ovarian cancer Mod Pathol 19 2006 607 610
36. H. Lassus, H. Sihto, A. Leminen, H. Joensuu, J. Isola, and N.N. Nupponen Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med 84 2006 671 681
37. K.D. Steffensen, M. Waldstrøm, D.A. Olsen, T. Corydon, K. Axelgaard Lorentzen, and H.J. Knudsen Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors Clin Cancer Res 14 2008 3278 3282
38. A. Mustea, J. Sehouli, G. Fabjani, D. Koensgen, V. Möbus, and E.I. Braicu Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study Anticancer Res 27 2007 1527 1530
39. A. Alvarez Secord, J.A. Blessing, D.K. Armstrong, W.H. Rodgers, Z. Miner, and M.N. Barnes Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study Gynecol Oncol 108 2008 493 499
40. L. Lacroix, P. Pautier, P. Duvillard, N. Motté, P. Saulnier, and J.M. Bidart Response of ovarian carcinomas to gefitnib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations Int J Cancer 118 2006 1068 1069
41. K.J. Kimball, T.M. Numnum, T.O. Kirby, W.C. Zamboni, J.M. Estes, and M.N. Barnes A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma Gynecol Oncol 111 2008 95 101
42. B.M. Slomovitz, R.L. Coleman, C. Levenback, M. Jung, D.M. Gershenson, and J. Wolf Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24, No 18S 2006 5090 abstract
43. D. Mavroudis, E. Efstathiou, A. Polyzos, A. Athanasiadis, G. Milaki, and E. Kastritis A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC) J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22, No 14S 2004 5020 abstract
44. S. Makhija, L.C. Amler, D. Glenn, F.R. Ueland, M.A. Gold, and D.S. Dizon Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 28 2010 1215 1223
45. P.A. Vasey, M. Gore, R. Wilson, G. Rustin, H. Gabra, and J.P. Guastalla A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers Br J Cancer 98 2008 1774 1780
46. J. Konner, R.J. Schilder, F.A. DeRosa, S.R. Gerst, W.P. Tew, and P.J. Sabbatini A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer Gynecol Oncol 110 2008 140 145
47. U. Wagner, A. du Bois, J. Pfisterer, J. Huoler, S. Loibi, and H.J. Lück Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) Gynecol Oncol 105 2007 132 137